Quick Answer
Transcode Therapeutics, Inc. reported Stockholders Equity of -$2.02 million for fiscal year 2024.
Transcode Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | -$2.02M | -223.0% |
| 2023 | $1.64M | -49.4% |
| 2022 | $3.24M | -84.1% |
| 2021 | $20.40M | +698.7% |
| 2020 | -$3.41M | -207.1% |
| 2019 | -$1.11M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.43M | -13.7% | -76.8% |
| June 30, 2025 | $6.15M | +364.9% | -40.3% |
| March 31, 2025 | $10.29M | +124.5% | +609.9% |
| December 31, 2024 | -$2.02M | -223.0% | -222.2% |
| September 30, 2024 | $1.65M | -62.8% | +24.9% |
| June 30, 2024 | $1.32M | -36.8% | -71.2% |
| March 31, 2024 | $4.58M | +2036.0% | +179.4% |
| December 31, 2023 | $1.64M | -49.4% | -63.0% |
- Transcode Therapeutics, Inc. showed a decrease of -223.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2024 period, Transcode Therapeutics, Inc.’s stockholders equity has declined by 81.9% (from -$1.11 million to -$2.02 million).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: